Concepedia

Amita Patnaik

AP

225

Publications

34.4K

Citations

77

H-Index

2000

Active since

Affiliations

South Texas Accelerated Research Therapeutics(Current)

The University of Texas MD Anderson Cancer Center

Dana-Farber Cancer Institute

Merck & Co., Inc., Rahway, NJ, USA (United States)

University of California, San Francisco

Amita Patnaik is an author at South Texas Accelerated Research Therapeutics specializing in medicine, oncology, and cancer therapeutics.

ORCID

Top concepts

Publications per year

2000–2025

225

Publications

225

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Edward B. Garon, Naiyer A. Rizvi, Rina Hui et al. · New England Journal of Medicine · 2015 · 6.1K citations · Full text

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Omid Hamid, Caroline Robert, Adil Daud et al. · New England Journal of Medicine · 2013 · 3.4K citations · Full text

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Caroline Robert, Antoni Ribas, Jedd D. Wolchok et al. · The Lancet · 2014 · 1.7K citations

, , +10

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

Corey J. Langer, Shirish M. Gadgeel, Hossein Borghaei et al. · The Lancet Oncology · 2016 · 1.4K citations

, , +7

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

Antoni Ribas, Omid Hamid, Adil Daud et al. · JAMA · 2016 · 1K citations · Full text

Rows per page

1–5 of 225